PIR International was delighted to partner with Dr Neil Torbett and the Board at PhoreMost on the appointment of Barbara Duncan as Chair and Stephen Dilly as Non-Executive Director.
PhoreMost is a UK-based biopharmaceutical company pioneering next-generation drug discovery through its proprietary SITESEEKER® platform. By exploiting the inherent complexity of protein shape diversity, PhoreMost identifies novel and unanticipated druggable targets across a wide range of diseases. The company’s approach accelerates the development of new therapeutics by linking phenotype-driven screening with actionable drug discovery, opening up vast untapped areas of the human proteome to drug development.
Barbara Duncan is an accomplished biopharma professional with an impressive executive and non-executive portfolio career. With over 25 years’ leadership experience, she has contributed her notable corporate finance background to a series of high-profile exits as board director. Barbara has led companies through IPOs totalling over $140 million, raised $1.5 billion in financing, and oversaw multiple strategic exits, demonstrating broad expertise in finance, M&A, and operational scaling for small molecule and oncology-focused platforms.
Stephen Dilly has a strong track record of advancing multiple therapeutic programmes through clinical development and taking several companies to exit, with total transactions valued at over $4 billion. He has held C-level, VP and board positions across an established portfolio of therapeutic and platform companies. Stephen brings deep oncology experience, and as CEO of Sierra Oncology, was instrumental in advancing the lead programme, Momelotinib, through Phase III trials and overseeing its $1.9B acquisition by GSK (2022). Stephen currently serves as CEO and Chair of Codexis.
Dr Neil Torbett, Chief Executive Officer of PhoreMost, stated:“Welcome to both Barbara and Stephen, we are delighted for them to join the Board. Their exceptional strategic and commercial leadership will be invaluable as we continue to progress differentiated degrader assets and commercialise our GlueSEEKER platform, which has recently passed significant chemical translation milestones. And of course, a big thank you to Chris for all he has done, and continues to do for PhoreMost as we progress in our mission to develop the next generation of therapies.”
Barbara Duncan, Chair and Non-Executive Director, PhoreMost, commented: “The PhoreMost team has made excellent progress in developing novel therapeutic approaches within the field of TPD. With its impressive capital raised to date and the calibre of its industry partnerships, the team is making strong headway with its pipeline of degrader-based therapeutics, and I look forward to working closely with them to support the company’s continued growth.”
Stephen Dilly, Non-Executive Director, PhoreMost, said: “TPD is a rapidly expanding and evolving modality, which has the potential to transform treatment for patients with currently untreatable conditions. This is a fantastic time to join PhoreMost and be a part of the team as they continue to address key challenges with molecular glue discovery, enabling the development of novel degrader-based therapeutics to revolutionise the future of medicine.”
Click here to read more: PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics